Use of Zoledronic Acid in a Neonate with Subcutaneous Fat Necrosis Complicated with Severe, Refractory Hypercalcemia

Am J Perinatol. 2019 Jul;36(S 02):S134-S138. doi: 10.1055/s-0039-1691777. Epub 2019 Jun 25.

Abstract

Objective: Subcutaneous fat necrosis (SCFN) is a rare condition that may occur in the neonatal period. SCFN is an inflammatory disorder of the adipose tissue, usually found in full-term healthy infants who have a history of intrauterine or perinatal distress. It is usually a self-limited condition; however, in some cases, it can get complicated, leading to severe hypercalcemia that may be life-threatening.

Study design: We report and describe a classic presentation of SCFN that led to severe hypercalcemia refractory to standard treatment. The diagnosis of SCFN was made based on the finding of subcutaneous nodules and of hypercalcemia. The serum calcium level reached 16.6 mg/dL. Hypercalcemia was treated first with intravenous infusions of fluids and furosemide and then of methylprednisolone. This standard treatment was not effective; therefore, we administered a single low dose of zoledronic acid, which, in turn, was efficacious in ultimately managing the hypercalcemia.

Conclusion: Our case shows how a single low dose of zoledronic acid was safe and effective in managing severe hypercalcemia unresponsive to conventional treatment while minimizing the risk of hypocalcemic rebounds.

Publication types

  • Case Reports

MeSH terms

  • Bone Density Conservation Agents / administration & dosage*
  • Calcium / blood
  • Drug Resistance
  • Fat Necrosis / complications*
  • Female
  • Furosemide / therapeutic use
  • Glucocorticoids / therapeutic use
  • Humans
  • Hypercalcemia / drug therapy*
  • Hypercalcemia / etiology
  • Infant, Newborn
  • Methylprednisolone / therapeutic use
  • Sodium Potassium Chloride Symporter Inhibitors / therapeutic use
  • Subcutaneous Fat
  • Term Birth
  • Zoledronic Acid / administration & dosage*

Substances

  • Bone Density Conservation Agents
  • Glucocorticoids
  • Sodium Potassium Chloride Symporter Inhibitors
  • Zoledronic Acid
  • Furosemide
  • Calcium
  • Methylprednisolone